A Trial of Shengmai Liquid for Long COVID Fatigue.

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

November 30, 2026

Conditions
Long COVID Fatigue
Interventions
DRUG

Shengmai Liquid

The Shengmaiyin treatment group will be given the traditional Chinese medicine Shengmaiyin oral liquid (produced by Jilin Aodong Yanbian Pharmaceutical Co., Ltd., with the approval number Z41021384. Ingredients: Codonopsis pilosula, Ophiopogon japonicus, Schisandra chinensis, excipients: sucrose, sodium benzoate, ethylparaben, specification 10m1/bottle), taken orally at a dose of 10ml per time, three times a day

OTHER

Placebo

A simulated Shengmaiyin oral liquid (provided by Jilin Aodong Yanbian Pharmaceutical Co., Ltd., with main ingredients water, brown sugar, flavoring agents, etc., specification 10m/bottle), 10ml per time, three times a day. The treatment course for Shengmaiyin or placebo will be 8 weeks (56 days), with follow-up continuing until 30 days after the end of the treatment course.

All Listed Sponsors
collaborator

Institute of Chemistry - Vietnam Academy of Science and Technology

UNKNOWN

collaborator

Beijing Ditan Hospital

OTHER

lead

Beijing University of Chinese Medicine

OTHER